Evidence map›Paper›PMID 28423625›Full record

ArticleOncotarget2017

Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer.

Yaxiong Cai, Shuange Yao, Jiangchuan Zhong, Jinxia Zhang, Haowu Jiang, Yanrui Deng, Ning Deng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Lymphatic transport in anti-tumor immunity and metastasis.The Journal of experimental medicine · 2025
    Review
  2. Article
  3. Review
  4. Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.International journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yaxiong CaiGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Shuange YaoGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Jiangchuan ZhongGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Jinxia ZhangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Haowu JiangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Yanrui DengGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Ning DengGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology in Jinan University, Guangzhou, China.
Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The over-expression of basic fibroblast growth factor (bFGF) plays a crucial role in the development, invasion and metastasis of lung cancer. Therefore, neutralizing antibodies against bFGF may inhibit the growth of lung cancer. In this study, a Disulfide-stabilized diabody (ds-Diabody) against bFGF was constructed by site-directed mutation and overlap extension PCR (SOE-PCR) at the position of VH44 and VL100 in the scFv. The ds-Diabody was constructed and expressed in Pichia pastoris. We found that the ds-Diabody against bFGF could efficiently suppress the proliferation, migration and invasion of human lung cancer A549 cells in vitro. Moreover, in A549 cells, the ds-Diabody against bFGF could inhibit bFGF-induced activation of downstream signaling regulators, such as phospho-Akt and phospho-MAPK. In the nude mouse xenograft model of lung cancer, the ds-Diabody against bFGF could significantly inhibit tumor growth and decrease the densities of micro-vessels and lymphatic vessels in tumor tissue. Our data indicate that the ds-Diabody against bFGF could effectively suppress the lung cancer growth through blockade of bFGF signaling pathway and inhibition of tumor angiogenesis, which may make it a potential therapeutic candidate antibody drug for human lung cancer therapy.

Indexed as

AnimalsApoptosisBiomarkers, TumorCell MovementCell ProliferationDisulfidesFemaleFibroblast Growth Factor 2HumansImmunoglobulin Variable RegionLung NeoplasmsMiceMice, Inbred BALB CMice, NudeNeovascularization, PathologicSignal TransductionBiomarkers, TumorDisulfidesFibroblast Growth Factor 2Immunoglobulin Variable RegionSingle-Chain AntibodiesangiogenesisbFGFds-diabodylung cancerlymphangiogenesis

Identifiers

PMID28423625
PMCPMC5386754
OpenAlexW2590567045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.